Siemens Medical Systems this month announced an addition to its MRI product lineup for the upcoming Radiological Society of North America meeting. The work-in-progress device, OR Open, is an intraoperative MR unit that combines Siemens' open system
Siemens Medical Systems this month announced an addition to its MRI product lineup for the upcoming Radiological Society of North America meeting. The work-in-progress device, OR Open, is an intraoperative MR unit that combines Siemens' open system Magnetom Open Viva with a new table that enables surgeons to do interventional MRI procedures in an operating room suite.
The scanner's height-adjustable table swings out and can be tilted up and down, giving surgeons 360 access to patients and the ability to position patients' organs in a way comparable to routine surgery. OR Open allows surgery to be done close to the magnet, which eliminates the need to move patients once the procedure has begun. The table's position flexibility allows surgeons to use both the magnet and other imaging devices such as x-ray or ultrasound, according to Dr. Jonathan Lewin, director of MRI at University Hospitals of Cleveland, where Siemens has placed the first OR Open.
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.